Zenas BioPharma, Inc. (ZBIO)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS98937L1052
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Zenas BioPharma, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 12 Nov 2026 20:50. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 16 Mar 2027 09:00 | -1.31 | — | — | Upcoming |
| 05 Nov 2026 07:00 | -1.27 | -1.23 | +3.1% | Beat |
| 13 Aug 2026 07:00 | -0.75 | -1.77 | -134.4% | Miss |
| 13 May 2026 06:00 | -1.54 | -1.46 | +5.2% | Beat |
| 16 Mar 2026 07:00 | -1.19 | -1.39 | -16.8% | Miss |
| 12 Nov 2025 07:00 | -0.85 | -1.22 | -44.1% | Miss |
| 12 Aug 2025 07:00 | -1.06 | -1.25 | -17.9% | Miss |
| 15 May 2025 07:00 | -1.03 | -0.80 | +22.3% | Beat |
| 12 Nov 2024 07:00 | -9.30 | -5.02 | +46.1% | Beat |
| 22 Aug 2024 14:00 | -1.24 | -2.79 | -125.0% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 10M | +100.0% | -377.7M | -3,777.4% | -8.44 | +29.0% | -207.4M |
| 2024 | 5M | -90.0% | -157M | -3,139.8% | -11.89 | -457.8% | -119.8M |
| 2023 | 50M | — | -37.1M | -74.2% | -2.13 | +77.0% | -30.5M |
| 2022 | 0 | — | -119.3M | — | -9.26 | — | -67.9M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 12 Nov 2026 | 28.18 | 28.75 | 27.42 | 27.78 | -3.21% | 551,774 | |
| 11 Nov 2026 | 28.95 | 29.50 | 28.50 | 28.70 | +0.42% | 306,300 | |
| 10 Nov 2026 | 28.22 | 29.89 | 28.11 | 28.58 | +0.04% | 304,700 | |
| 09 Nov 2026 | 28.75 | 30.02 | 27.80 | 28.57 | +1.10% | 634,900 | |
| 06 Nov 2026 | 26.21 | 28.44 | 25.83 | 28.26 | +8.99% | 544,000 | |
| 05 Nov 2026 | 28.10 | 28.49 | 25.79 | 25.93 | -8.89% | 824,100 | |
| 04 Nov 2026 | 29.27 | 29.91 | 28.01 | 28.46 | +0.28% | 800,700 | |
| 03 Nov 2026 | 27.85 | 29.05 | 27.83 | 28.38 | +2.75% | 572,800 | |
| 02 Nov 2026 | 28.47 | 29.09 | 27.15 | 27.62 | -2.71% | 408,300 | |
| 30 Oct 2026 | 28.35 | 29.11 | 27.91 | 28.39 | -1.29% | 358,100 | |
| 534 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference (opens in a new tab) 09 Nov 2026 12:00
- Zenas BioPharma (ZBIO) After Third Quarter Losses Still Carries An Undervalued Narrative (opens in a new tab) Simply Wall St. · 07 Nov 2026 06:11
- Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update (opens in a new tab) 05 Nov 2026 12:00
- Zenas BioPharma Q3 EPS $(1.65) Misses $(1.33) Estimate, Sales $10.000M (opens in a new tab) Benzinga · 05 Nov 2026 08:51
- Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears (opens in a new tab) MarketBeat · 30 Oct 2026 15:14
- Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know (opens in a new tab) Zacks · 23 Oct 2026 13:55
- Zenas BioPharma Stock Gains Attention After Long Term Trial Data (opens in a new tab) Simply Wall St. · 21 Oct 2026 01:17
- Zenas BioPharma (ZBIO) Is Down 5.1% After New Phase 3 Obexelimab IgG4-RD Data Release (opens in a new tab) Simply Wall St. · 13 Oct 2026 09:18
- Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn? (opens in a new tab) Insider Monkey · 23 Sep 2026 12:14
- Why Is Zenas BioPharma (ZBIO) Filing More Than $240 Million In Shelves? (opens in a new tab) Simply Wall St. · 23 Sep 2026 05:32
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 28.70 USD
- Market cap
- 1.9B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow ZBIO and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.